AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ACTINOGEN MEDICAL LTD

0.041

-0.001-2.38%

Volume:2.10M

Turnover:88.01K

Market Cap:141.93M

PE:-8.29

High:0.043

Open:0.041

Low:0.041

Close:0.042

52wk High:0.072

52wk Low:0.019

Shares:3.46B

Float Shares:2.61B

Volume Ratio:0.78

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.005

EPS(LYR):-0.005

ROE:-110.77%

ROA:-63.87%

PB:16.96

PE(LYR):-8.29

Loading ...

Overview Company News Filings

Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives

Simply Wall St.

BRIEF-Actinogen Medical Completes A$16.8M Placement And Spp

Actinogen Medical Ltd - Completes a$16.8M Placement and Spp

THOMSON REUTERS

Actinogen Medical Receives Green Light to Continue Pivotal XanaMIA Alzheimer’s Trial

Actinogen Medical to Raise AU$12 Million via Share Placement

MT Newswires Live

BRIEF-Actinogen Medical To Raise A$12.0 Million

Actinogen Medical Ltd - to Raise a$12.0 Mln at a$0.042 per Share

THOMSON REUTERS

BRIEF-Actinogen Medical Seeks Trading Halt

Actinogen Medical Ltd - Seeks Trading Halt Pending Xanamia Alzheimer's Trial Analysis Outcome

THOMSON REUTERS

Building a lazy ETF portfolio in 2026

Morning Star AU

ASX Penny Stocks To Watch In December 2025

Simply Wall St.

BRIEF-Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial

Final, 247TH Participant Randomized and Commences Treatment in Actinogen’s Xanamia Pivotal Phase 2B/3 Alzheimer’s Trial

THOMSON REUTERS

Actinogen Medical Ltd - Topline Final Results for Xanamia Trial in November 2026

THOMSON REUTERS

Actinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial

MT Newswires Live

Actinogen Medical Ltd-Acw CEO & CFO Present at Bell Potter Healthcare Conference

THOMSON REUTERS

Actinogen Medical Ltd-Acw Progress Update and Q&a Webinar Today

THOMSON REUTERS

Actinogen Medical Ltd-Advance Notice Acw Progress Update and Q&a Webinar

THOMSON REUTERS

Actinogen Medical Ltd-Acw September 2025 Quarterly Activity Report & Appendix 4C

THOMSON REUTERS

Actinogen Medical Ltd-Acw CEO Presents at Canaccord Drug & Device Conference

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACW.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACW.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.041,"timestamp":1772169120000,"preClose":0.042,"halted":0,"volume":2098999,"delay":0,"changeRate":-0.02380952380952383,"nameEN":"ACTINOGEN MEDICAL LTD","floatShares":2607880613,"shares":3461769000,"eps":-0.004944,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"02-27 16:12:00 AEDT","open":0.041,"high":0.043,"low":0.041,"amount":88013,"amplitude":0.047619,"askPrice":0.043,"askSize":388075,"bidPrice":0.041,"bidSize":720164,"shortable":3,"etf":0,"ttmEps":-0.004944,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772406000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.042,"openAndCloseTimeList":[[1772146800000,1772168400000]],"volumeRatio":0.7802187141299636,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2607880613,"roa":"-63.87%","roe":"-110.77%","lyrEps":-0.004944,"volumeRatio":0.7802187141299636,"shares":3461769000,"dividePrice":0,"high":0.043,"amplitude":0.047619,"preClose":0.042,"low":0.041,"week52Low":0.019,"pbRate":"16.96","psRate":"19.30","week52High":0.072,"institutionHeld":0,"latestPrice":0.041,"committee":0.299655,"eps":-0.004944,"divideRate":0,"volume":2098999,"delay":0,"ttmEps":-0.004944,"open":0.041,"prevYearClose":0.061,"prevWeekClose":0.042,"prevMonthClose":0.041,"prevQuarterClose":0.061,"fiveDayClose":0.042,"twentyDayClose":0.045,"sixtyDayClose":0.059,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614858228","title":"Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2614858228","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614858228?lang=en_us&edition=fundamental","pubTime":"2026-02-27 16:43","pubTimestamp":1772181827,"startTime":"0","endTime":"0","summary":"Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash the business is consuming rather than generating. The company has seen reported half year revenue move between A$9.0 million in H2 2024, A$0 in H1 2025 and A$5.5 million in H2 2025, alongside basic EPS losses of A$0.0007, A$0.0028 and A$0.0022 respectively, so investors are likely to be weighing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACW.AU","BK7508","BK7067","TTM","BK4099","BK4523"],"gpt_icon":0},{"id":"2614900988","title":"BRIEF-Actinogen Medical Completes A$16.8M Placement And Spp","url":"https://stock-news.laohu8.com/highlight/detail?id=2614900988","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614900988?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:39","pubTimestamp":1772156345,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Completes A$16.8M Placement And SppFeb 27 (Reuters) - Actinogen Medical Ltd ACW.AX:COMPLETES A$16.8M PLACEMENT AND SPPFurther company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM27G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2614724410","title":"Actinogen Medical Ltd -  Completes a$16.8M Placement and Spp","url":"https://stock-news.laohu8.com/highlight/detail?id=2614724410","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614724410?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:34","pubTimestamp":1772145263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM27G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"gpt_icon":0},{"id":"2608618528","title":"Actinogen Medical Receives Green Light to Continue Pivotal XanaMIA Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608618528","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608618528?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037244,"startTime":"0","endTime":"0","summary":"Actinogen Medical Ltd. has announced that its independent Data Monitoring Committee has recommended the continuation of the XanaMIA pivotal Alzheimer's disease trial following a positive interim analysis of unblinded safety and efficacy data. The trial is fully enrolled, and topline final results are expected to be reported in November 2026. Following the completion of the trial, results will be presented at a key Alzheimer's disease scientific meeting and published in a peer-reviewed journal. All participants in the XanaMIA trial are eligible for an open-label extension phase, during which they will receive Xanamem 10 mg for up to 25 months. Additionally, a second and larger global pivotal trial is planned to commence in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDLb1HFgw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","BK7508","LU0314104364.USD","SG9999014005.SGD","SG9999014039.USD","BK7067","NDAQ","IE00BKPKM429.USD","ACW.AU","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4588"],"gpt_icon":0},{"id":"2608835297","title":"Actinogen Medical to Raise AU$12 Million via Share Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608835297","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608835297?lang=en_us&edition=fundamental","pubTime":"2026-02-02 10:32","pubTimestamp":1769999544,"startTime":"0","endTime":"0","summary":"Actinogen Medical (ASX:ACW) received firm commitments to raise about AU$12 million through the issue of 285.7 million shares at AU$0.042 apiece, according to a Monday filing with the Australian bourse","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2608583394","title":"BRIEF-Actinogen Medical To Raise A$12.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608583394","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608583394?lang=en_us&edition=fundamental","pubTime":"2026-02-02 09:53","pubTimestamp":1769997235,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical To Raise A$12.0 MillionFeb 2 (Reuters) - Actinogen Medical Ltd ACW.AX:TO RAISE A$12.0 MILLION AT A$0.042 PER SHAREFurther company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YV1T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2608882347","title":"Actinogen Medical Ltd -  to Raise a$12.0 Mln at a$0.042 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2608882347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608882347?lang=en_us&edition=fundamental","pubTime":"2026-02-02 06:57","pubTimestamp":1769986666,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nFWN3YV1T5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2607672544","title":"BRIEF-Actinogen Medical Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2607672544","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607672544?lang=en_us&edition=fundamental","pubTime":"2026-01-29 06:04","pubTimestamp":1769637881,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Medical Seeks Trading HaltJan 29 (Reuters) - Actinogen Medical Ltd ACW.AX:SEEKS TRADING HALT PENDING XANAMIA ALZHEIMER'S TRIAL ANALYSIS OUTCOMEFurther company coverage: ACW.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT16L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2607445725","title":"Actinogen Medical Ltd - Seeks Trading Halt Pending Xanamia Alzheimer's Trial Analysis Outcome","url":"https://stock-news.laohu8.com/highlight/detail?id=2607445725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607445725?lang=en_us&edition=fundamental","pubTime":"2026-01-29 06:04","pubTimestamp":1769637857,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT16L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2605343367","title":"Building a lazy ETF portfolio in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2605343367","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605343367?lang=en_us&edition=fundamental","pubTime":"2026-01-21 00:00","pubTimestamp":1768924800,"startTime":"0","endTime":"0","summary":"In my original article, I decided on a 50:50 allocation between a US stock ETF  and a World ex-US ETF (main options are ASX: VEU, ASX: EXU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/etfs/building-lazy-etf-portfolio-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/etfs/building-lazy-etf-portfolio-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["BK7508","BGBL.AU","VGS.AU","IVV.AU","EXUS.AU","FDN","BK4585","BK4581","VTS.AU","XAO.AU","BK4550","ACW.AU","VDHG.AU","VEU.AU","XJO.AU","VGB.AU","BK4588","XKO.AU","BK7067"],"gpt_icon":1},{"id":"2593171285","title":"ASX Penny Stocks To Watch In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171285","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593171285?lang=en_us&edition=fundamental","pubTime":"2025-12-22 03:01","pubTimestamp":1766343710,"startTime":"0","endTime":"0","summary":"As Australian shares experience a modest uptick, following Wall Street's lead, investors are keenly observing the market dynamics influenced by global economic indicators. Amidst these developments, penny stocks remain an intriguing area of investment, offering potential opportunities in smaller or less-established companies. While the term \"penny stocks\" may seem outdated, these investments can still provide value when backed by strong financials and growth prospects.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8031000-choice2-main-header/1585186598236"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/asx-penny-stocks-to-watch-in-december-2025-10","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-apx/appen-shares/news/asx-penny-stocks-to-watch-in-december-2025-10","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7012","BK7132","WAF.AU","BK7104","ACW.AU","BK7506","MXI.AU","EZZ.AU","IGL.AU","BK7067","BK7048","EDU.AU","CXL.AU","BK7508","BK7128","DSK.AU","APX.AU","BK7045","BK7017","BK7014","BK7503","BK7061","FWD.AU","AAL.AU","BK7055","GWA.AU","SSM.AU","BK7077","BK7111"],"gpt_icon":0},{"id":"2592099549","title":"BRIEF-Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592099549","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592099549?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:33","pubTimestamp":1766064796,"startTime":"0","endTime":"0","summary":"BRIEF-Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s TrialDec 18 (Reuters) - Actinogen Medical Ltd ACW.AX:FINAL, 247TH PARTICIPANT RANDOMIZED AND COMMENCES TREATMENT IN ACTINOGEN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB1WPRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2592906318","title":"Final, 247TH Participant Randomized and Commences Treatment in Actinogen’s Xanamia Pivotal Phase 2B/3 Alzheimer’s Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906318?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB1WPRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2592069529","title":"Actinogen Medical Ltd - Topline Final Results for Xanamia Trial in November 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592069529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592069529?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:00","pubTimestamp":1766062804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB1WPRG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2592400839","title":"Actinogen Medical Starts Treatment of Patients in Alzheimer's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592400839","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592400839?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:44","pubTimestamp":1766022289,"startTime":"0","endTime":"0","summary":"Actinogen Medical  started treatment of all 246 patients in the XanaMIA phase 2b/3 Alzheimer's disease trial, and expects final results in November 2026, according to a Thursday filing with the Australian bourse.The company had earlier expected the results in the fourth quarter, the filing said.The trial will test whether the drug candidate Xanamem can slow the progression of Alzheimer's disease over 36 weeks in patients taking 10 milligrams of the drug or a placebo once daily, the filing added.An interim analysis of safety and efficacy futility from the partially completed trial will be conducted in January, the company said.The final analysis will compare the efficacy and safety of Xanamem with that of patients who received placebo, the company added.Shares of the company fell 2% in recent Thursday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2584616549","title":"Actinogen Medical Ltd-Acw CEO & CFO Present at Bell Potter Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584616549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584616549?lang=en_us&edition=fundamental","pubTime":"2025-11-19 06:37","pubTimestamp":1763505460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nTUE2TP8ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"gpt_icon":0},{"id":"2578711226","title":"Actinogen Medical Ltd-Acw Progress Update and Q&a Webinar Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2578711226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578711226?lang=en_us&edition=fundamental","pubTime":"2025-10-28 05:48","pubTimestamp":1761601690,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUE4XS7SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2577347509","title":"Actinogen Medical Ltd-Advance Notice Acw Progress Update and Q&a Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2577347509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577347509?lang=en_us&edition=fundamental","pubTime":"2025-10-23 10:24","pubTimestamp":1761186259,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUEC2XK6K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0},{"id":"2577310116","title":"Actinogen Medical Ltd-Acw September 2025 Quarterly Activity Report & Appendix 4C","url":"https://stock-news.laohu8.com/highlight/detail?id=2577310116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577310116?lang=en_us&edition=fundamental","pubTime":"2025-10-23 06:20","pubTimestamp":1761171633,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nTUE1RHYTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2577489960","title":"Actinogen Medical Ltd-Acw CEO Presents at Canaccord Drug & Device Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2577489960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577489960?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:52","pubTimestamp":1760997128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUE74BS1Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":27,"code":"91000000","status":"200"}]}}